- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05757349
Analysis of Novel Positioning Sensor-assisted Postoperative Position Correction and Effective Prone Time Recorded in Patients With Different Prone Times After Macular Hole Surgery
February 23, 2023 updated by: Bojie Hu, Tianjin Medical University Eye Hospital
A Prospective Study on the Prognosis of the Idiopathic Macular Hole With Different Prone Position Times Assisted by Novel Positioning Sensor
Idiopathic macular hole (IMH) is a fundus disease without clear etiology, most often seen in healthy women over 50 years of age, and is often associated with ocular manifestations such as loss of central vision and visual distortion.
It is often associated with loss of central vision, visual distortion, and other ocular manifestations.
It is currently treated by vitrectomy combined with internal limiting membranes (ILM) peeling followed by gas filling.
A strict prone position for a certain period of time after surgery has a positive effect on the healing of the macular fissure.
The need for a strict prone position after IMH has been demonstrated in previous studies (especially when the IMH diameter is >400 μm).
However, due to the anti-human mechanics of the face-down position, patient comfort, sleep quality and quality of life are greatly compromised.
Therefore, this study designed a smart head position monitoring device to assist patients in maintaining the correct position and recording the effective position time.
The study was conducted to determine the shortest prone position time based on macular fissure closure, to minimize the adverse effects of postoperative position, and to obtain the maximum recovery of visual acuity and visual field.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
86
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China
- Recruiting
- Tianjin medical university eye hosipital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients aged 18 years or older;
- Patients diagnosed with IMH;
- Patients requiring face-down position after vitrectomy combined with ILM peeling and C3F8(14%) gas filling; Tolerated face-down position after surgery;
- Agreed to the study protocol.
Exclusion Criteria:
- Myopia greater than or equal to -6.0 D; Eye axis length (AL) greater than 26.0mm;
- Trauma, macular edema, macular degeneration, and other secondary MH with clear etiology;
- Previous history of internal eye surgery in the operated eye;
- Patients with local or systemic other diseases significantly affecting visual function;
- Those who cannot maintain face-down position after surgery due to systemic factors, etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Face-down position time 1-day group
Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
|
Postoperative face-down position of subjects wearing the novel positioning sensor device for 1-day.
|
|
Active Comparator: Face-down position time 3-day group
Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
|
Postoperative face-down position of subjects wearing the novel positioning sensor device for 3-day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Macular hole closure rate
Time Frame: 6 month postoperatively
|
Ratio of patients with postoperative lacunae that remained closed until the end of the follow-up time to the number of patients who reopened during the follow-up time of those who did not close after surgery
|
6 month postoperatively
|
|
Effective face-down position time
Time Frame: 1 or 3 day postoperatively
|
Novel positioning sensor related data cloud storage platform can record and extract effective face-down position time.
|
1 or 3 day postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Best corrected visual acuity change (BCVA)
Time Frame: 1, 3, 6 month postoperatively
|
BCVA for patients after macular fissure surgery, expressed using the (ETDRS) Alphabet Chart.
|
1, 3, 6 month postoperatively
|
|
Retinal nerve fiber layer thickness change
Time Frame: 1, 3, 6 month postoperatively
|
Three-dimensional spectral domain optical coherence tomography (SD-OCT)
|
1, 3, 6 month postoperatively
|
|
Macular ganglion cell complex thickness change (GCL+, GCL++)
Time Frame: 1, 3, 6 month postoperatively
|
Three-dimensional spectral domain optical coherence tomography (SD-OCT)
|
1, 3, 6 month postoperatively
|
|
Mean retinal Sensitivity (MS)
Time Frame: 1, 3, 6 month postoperatively
|
Micro Perimeter 3
|
1, 3, 6 month postoperatively
|
|
Central 2˚ and 4˚ fixation
Time Frame: 1, 3, 6 month postoperatively
|
Micro Perimeter 3
|
1, 3, 6 month postoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2022
Primary Completion (Anticipated)
March 30, 2024
Study Completion (Anticipated)
March 30, 2024
Study Registration Dates
First Submitted
February 14, 2023
First Submitted That Met QC Criteria
February 23, 2023
First Posted (Estimate)
March 7, 2023
Study Record Updates
Last Update Posted (Estimate)
March 7, 2023
Last Update Submitted That Met QC Criteria
February 23, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TianjinMUEHhbj456
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Macular Hole
-
The Filatov Institute of Eye Diseases and Tissue...Ukrainian Vitreoretinal SocietyEnrolling by invitationMacular Holes | Idiopathic Macular Hole | Macular Hole | Full Thickness Macular HoleUkraine
-
Jie ZhongEnrolling by invitationMacular Hole Surgery | Idiopathic Macular Hole | Macular Hole | Macular Hole of Left Eye (Disorder) | Macular Hole of Right Eye (Disorder)China
-
University of LuebeckCompletedIdiopathic Macular HoleGermany
-
Fondation Ophtalmologique Adolphe de RothschildCompletedIdiopathic Macular Hole
-
University of CoimbraCompleted
-
Glostrup University Hospital, CopenhagenThe Danish Medical Research Council; Danish Eye Health SocietyCompletedIdiopathic Macular HoleDenmark
-
Peking University People's HospitalPeking Union Medical College Hospital; Beijing Tongren Hospital; Beijing HospitalUnknown
-
Centre Hospitalier Universitaire DijonCompleted
-
The Ludwig Boltzmann Institute of Retinology and...Completed
Clinical Trials on Face-down position time 1-day
-
The Fourth Affiliated Hospital of Zhejiang University...Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Nijznevartovsk County Clinical HospitalCompletedHernia, VentralRussian Federation
-
CASI Pharmaceuticals, Inc.CompletedRecurrent Glioblastoma MultiformeUnited States
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2Mexico, United States, Estonia, Bulgaria, Latvia, Romania, Lithuania, Puerto Rico, Costa Rica
-
Assistance Publique - Hôpitaux de ParisRecruitingAcute Lymphoblastic Leukemia, in Relapse | B Acute Lymphoblastic LeukemiaFrance
-
Sparrow PharmaceuticalsCompletedA Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62Obesity | Type 2 Diabetes Mellitus in Obese | Type2DiabetesUnited States
-
Xijing HospitalUnknownRheumatoid Arthritis | Major Depressive DisorderChina
-
Nantes University HospitalTerminated
-
DongE E Jiao Coporation LimitedCompletedPostpartum AnemiaChina
-
Bahria UniversityActive, not recruiting